A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Belgium

Centre for the Evaluation of Vaccination (CEV), Antwerp

University Hospital Ghent - Centrum voor Vaccinologie (CEVAC), Ghent